ForumIAS LATEST
- 07 Sept. | From Preparation to Mains Readiness: Making the Next Four Months Count Click Here to Read More →
- 07 Sept. | Interview Preparation & Way Ahead After Mains 2026 by Ayush Sir Click Here to Register →
- 07 Sept. | Do you know what is better than MGP and Current Affairs? Click Here to Read More →
- 31 Aug. | Upcoming programs by forumiAS For UPSC CSE 2027 Click Here to Read More →
News: WHO has endorsed a new class of drug, GLP-1 Receptor Agonists, for managing obesity.
About GLP-1 Receptor Agonists
- Role: They mimic a hormone that regulates appetite and blood sugar level, lipid metabolism, and other biological functions.
- Drugs in this class include semaglutide and tirzepatide, which have potential to be transformative.
- Utility:
- Helps in treatment of Type 2 diabetes and obesity.
- These drugs can complement current policies promoting healthy eating and physical exercise to curb the obesity pandemic.
- These drugs are significant as obesity affects nearly 1 in 8 people worldwide.
- Side Effects: There are severe side effects like stomach paralysis, inflamed pancreas and thyroid cancer.
